CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

EluRyng

etonogestrel and ethinyl estradiol· ingredient etonogestrelEstrogens· ETHINYL ESTRADIOL .015 mg/d; ETONOGESTREL .12 mg/d
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$48.54
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Medicare Part D coverage · CY2026

On 324 plan formularies · typical tier 3
Prior auth 0% · Step therapy 0% · Quantity limit 31% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.